Clinical trialPhase 1Completed
A Dose Escalation Safety Study of Locally-Delivered Gemcitabine in Pancreatic Cancer
A Dose Escalation Safety Study of Locally-Delivered (Intra-Arterial) Gemcitabine in Unresectable Adenocarcinoma of the Pancreas
- Outcome
- Outcome unknown
- Phase
- Phase 1
- Status
- Completed
- Study type
- Interventional
- Start
- March 2015
- Expected end
- September 2016
- Enrollment
- 20 participants
- Sites
- 2
- Primary outcomes
- Determine the Maximum Tolerated Dose of Gemcitabine to be Delivered Locally to the Pancreas
- Sponsor
- Industry
- Results posted
- 2021-05-07
- Last update
- 7 May 2021
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
A dose escalation, safety study of local (intra-arterially) delivered gemcitabine to the pancreas using the RenovoCath R120 catheter to determine the maximum tolerated dose.
Detailed description public domain (ClinicalTrials.gov)
Patients diagnosed with unresectable pancreatic cancer who may or may not have had prior chemotherapy or radiation therapy may be eligible to enroll in this dose escalation study to determine the maximum tolerated dose of gemcitabine to be delivered locally to the pancreatic tumors using the RenovoCath R120 catheter. Patients enrolled may receive up to 8 catheterizations for delivering gemcitabine directly to the pancreatic tumors starting at a reduced dose( 1/4 of standard i.v. gemcitabine dose), then every two doses, increase the dose by 25% if there are no toxicities up to a maximum dose of 1000 mg/m2. There are four cycles, with two doses per cycle. Imaging studies will be conducted as well as assessment for standard, myelosuppresive and gastric toxicities will be assessed. Pain will also be measured throughout the study.
Posted results (ClinicalTrials.gov registry) · primary outcome public domain (ClinicalTrials.gov)
Determine the Maximum Tolerated Dose of Gemcitabine to be Delivered Locally to the Pancreas [1 week post treatment]. Number, mg/m^2. Gemcitabine, Local Delivery (n=20): 1000.